1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Introduction
2.2. Define: Research Objective
2.3. Determine: Research Design
2.4. Prepare: Research Instrument
2.5. Collect: Data Source
2.6. Analyze: Data Interpretation
2.7. Formulate: Data Verification
2.8. Publish: Research Report
2.9. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19

6. Ankylosing Spondylitis Market, by Drug
6.1. Introduction
6.2. Cimzia
6.3. Cosentyx
6.4. Enbrel
6.5. Humira
6.6. Remicade
6.7. Simponi

7. Ankylosing Spondylitis Market, by Type of Molecule
7.1. Introduction
7.2. Biologics
7.3. Small Molecules

8. Ankylosing Spondylitis Market, by Mechanism Of Action
8.1. Introduction
8.2. COX Inhibitors
8.3. TNF Inhibitors

9. Ankylosing Spondylitis Market, by Route Of Administration
9.1. Introduction
9.2. Oral
9.3. Parenteral

10. Ankylosing Spondylitis Market, by Dosage Forms
10.1. Introduction
10.2. Liquid
10.3. Solid

11. Ankylosing Spondylitis Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Hospitals

12. California Ankylosing Spondylitis Market

13. Florida Ankylosing Spondylitis Market

14. Illinois Ankylosing Spondylitis Market

15. New York Ankylosing Spondylitis Market

16. Ohio Ankylosing Spondylitis Market

17. Pennsylvania Ankylosing Spondylitis Market

18. Texas Ankylosing Spondylitis Market

19. Competitive Landscape
19.1. FPNV Positioning Matrix
19.1.1. Quadrants
19.1.2. Business Strategy
19.1.3. Product Satisfaction
19.2. Market Ranking Analysis
19.3. Market Share Analysis, By Key Player
19.4. Competitive Scenario
19.4.1. Merger & Acquisition
19.4.2. Agreement, Collaboration, & Partnership
19.4.3. New Product Launch & Enhancement
19.4.4. Investment & Funding
19.4.5. Award, Recognition, & Expansion

20. Company Usability Profiles
20.1. Abbvie Inc.
20.2. Amgen Inc.
20.3. Biothera Pharmaceuticals, Inc.
20.4. Bristol-Myers Squibb
20.5. C.H. Boehringer Sohn AG & Ko. KG
20.6. Cadila Healthcare Limited
20.7. Celgene Corporation
20.8. Celltrion
20.9. Eisai Co., Ltd
20.10. Eli Lilly and Company
20.11. F. Hoffmann-La Roche AG
20.12. Hetero Drugs Limited
20.13. Izana Bioscience
20.14. Johnson & Johnson Services, Inc.
20.15. Merck & Co., Inc
20.16. Novartis AG
20.17. Pfizer Inc.
20.18. Regeneron Pharmaceuticals, Inc
20.19. Reliance Life Sciences
20.20. Samsung Bioepis Co., Ltd.
20.21. Sandoz International GmbH
20.22. Sanofi SA
20.23. Shanghai Pharmaceuticals Holding Co., Ltd.
20.24. Trinity Biotech Ireland
20.25. UCB Inc.
20.26. Xian Janssen Pharmaceutical Ltd

21. Appendix
21.1. Discussion Guide
21.2. License & Pricing

List of Figures

FIGURE 1. UNITED STATES ANKYLOSING SPONDYLITIS MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES ANKYLOSING SPONDYLITIS MARKET: MARKET DYNAMICS
FIGURE 3. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2020 VS 2027 (%)
FIGURE 4. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2020 VS 2027 (USD MILLION)
FIGURE 5. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2027
FIGURE 6. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY CIMZIA, 2018-2027 (USD MILLION)
FIGURE 7. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY CIMZIA, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 8. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY COSENTYX, 2018-2027 (USD MILLION)
FIGURE 9. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY COSENTYX, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 10. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ENBREL, 2018-2027 (USD MILLION)
FIGURE 11. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ENBREL, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 12. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY HUMIRA, 2018-2027 (USD MILLION)
FIGURE 13. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY HUMIRA, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 14. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY REMICADE, 2018-2027 (USD MILLION)
FIGURE 15. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY REMICADE, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 16. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY SIMPONI, 2018-2027 (USD MILLION)
FIGURE 17. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY SIMPONI, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 18. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2020 VS 2027 (%)
FIGURE 19. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2020 VS 2027 (USD MILLION)
FIGURE 20. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2027
FIGURE 21. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2027 (USD MILLION)
FIGURE 22. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 23. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2027 (USD MILLION)
FIGURE 24. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 25. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2020 VS 2027 (%)
FIGURE 26. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2020 VS 2027 (USD MILLION)
FIGURE 27. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2027
FIGURE 28. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY COX INHIBITORS, 2018-2027 (USD MILLION)
FIGURE 29. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY COX INHIBITORS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 30. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2027 (USD MILLION)
FIGURE 31. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TNF INHIBITORS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 32. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2027 (%)
FIGURE 33. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2027 (USD MILLION)
FIGURE 34. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2027
FIGURE 35. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2027 (USD MILLION)
FIGURE 36. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 37. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY PARENTERAL, 2018-2027 (USD MILLION)
FIGURE 38. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY PARENTERAL, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 39. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2020 VS 2027 (%)
FIGURE 40. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2020 VS 2027 (USD MILLION)
FIGURE 41. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2027
FIGURE 42. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY LIQUID, 2018-2027 (USD MILLION)
FIGURE 43. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY LIQUID, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 44. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLID, 2018-2027 (USD MILLION)
FIGURE 45. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLID, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 46. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2020 VS 2027 (%)
FIGURE 47. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2020 VS 2027 (USD MILLION)
FIGURE 48. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2027
FIGURE 49. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY CLINICS, 2018-2027 (USD MILLION)
FIGURE 50. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY CLINICS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 51. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, 2018-2027 (USD MILLION)
FIGURE 52. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 53. UNITED STATES ANKYLOSING SPONDYLITIS MARKET: FPNV POSITIONING MATRIX
FIGURE 54. UNITED STATES ANKYLOSING SPONDYLITIS MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 55. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES ANKYLOSING SPONDYLITIS MARKET, BY TYPE

List of Tables

TABLE 1. UNITED STATES ANKYLOSING SPONDYLITIS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2027 (USD MILLION)
TABLE 4. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY CIMZIA, BY STATE, 2018-2027 (USD MILLION)
TABLE 5. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY COSENTYX, BY STATE, 2018-2027 (USD MILLION)
TABLE 6. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ENBREL, BY STATE, 2018-2027 (USD MILLION)
TABLE 7. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY HUMIRA, BY STATE, 2018-2027 (USD MILLION)
TABLE 8. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY REMICADE, BY STATE, 2018-2027 (USD MILLION)
TABLE 9. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY SIMPONI, BY STATE, 2018-2027 (USD MILLION)
TABLE 10. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2027 (USD MILLION)
TABLE 11. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, BY STATE, 2018-2027 (USD MILLION)
TABLE 12. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, BY STATE, 2018-2027 (USD MILLION)
TABLE 13. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2027 (USD MILLION)
TABLE 14. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY COX INHIBITORS, BY STATE, 2018-2027 (USD MILLION)
TABLE 15. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TNF INHIBITORS, BY STATE, 2018-2027 (USD MILLION)
TABLE 16. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 17. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY STATE, 2018-2027 (USD MILLION)
TABLE 18. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY PARENTERAL, BY STATE, 2018-2027 (USD MILLION)
TABLE 19. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2027 (USD MILLION)
TABLE 20. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY LIQUID, BY STATE, 2018-2027 (USD MILLION)
TABLE 21. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLID, BY STATE, 2018-2027 (USD MILLION)
TABLE 22. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2027 (USD MILLION)
TABLE 23. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY CLINICS, BY STATE, 2018-2027 (USD MILLION)
TABLE 24. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY STATE, 2018-2027 (USD MILLION)
TABLE 25. UNITED STATES ANKYLOSING SPONDYLITIS MARKET: SCORES
TABLE 26. UNITED STATES ANKYLOSING SPONDYLITIS MARKET: BUSINESS STRATEGY
TABLE 27. UNITED STATES ANKYLOSING SPONDYLITIS MARKET: PRODUCT SATISFACTION
TABLE 28. UNITED STATES ANKYLOSING SPONDYLITIS MARKET: RANKING
TABLE 29. UNITED STATES ANKYLOSING SPONDYLITIS MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 30. UNITED STATES ANKYLOSING SPONDYLITIS MARKET: MERGER & ACQUISITION
TABLE 31. UNITED STATES ANKYLOSING SPONDYLITIS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 32. UNITED STATES ANKYLOSING SPONDYLITIS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 33. UNITED STATES ANKYLOSING SPONDYLITIS MARKET: INVESTMENT & FUNDING
TABLE 34. UNITED STATES ANKYLOSING SPONDYLITIS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 35. UNITED STATES ANKYLOSING SPONDYLITIS MARKET: LICENSE & PRICING

Companies Mentioned

Abbvie Inc.
Amgen Inc.
Biothera Pharmaceuticals, Inc.
Bristol-Myers Squibb
C.H. Boehringer Sohn AG & Ko. KG
Cadila Healthcare Limited
Celgene Corporation
Celltrion
Eisai Co., Ltd
Eli Lilly and Company
F. Hoffmann-La Roche AG
Hetero Drugs Limited
Izana Bioscience
Johnson & Johnson Services, Inc.
Merck & Co., Inc
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals, Inc
Reliance Life Sciences
Samsung Bioepis Co., Ltd.
Sandoz International GmbH
Sanofi SA
Shanghai Pharmaceuticals Holding Co., Ltd.
Trinity Biotech Ireland
UCB Inc.
Xian Janssen Pharmaceutical Ltd